Janice Murray, president of Novartis Pharmaceuticals Canada Inc., highlights the track record of excellence Novartis has enjoyed in Canada as the second largest pharma affiliate in the country, the challenge of adapting to an increasingly uncertain market access environment, and the exciting initiatives through which Novartis is delivering innovations and value to patients and healthcare stakeholders in Canada.
Janice, you were appointed president in May 2017, but you are no stranger to the Novartis organization in Canada. What have been your priorities over the past few months?
"Novartis’ mantra is to either be first- or best-in-class. We are not going to introduce a ‘me, too’ drug."
